Late-Phase Research for Pharma and Biotechs
With accelerated approvals and regulatory focus on risk management and mitigation strategies, the need has never been greater for healthcare companies to be diligent when it comes to late-phase or peri-approval research.
Kantar has more than 30 years of clinical research experience and can design a customised study to meet the needs of your product or research area. Our solutions enable you to adhere to risk management requirements, establish evidence for safety issues, and assess health outcomes and economics in various settings.
Also within Health
Data and Analytics
Clinical Research & Medical Affairs